Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NASDAQ:HYPD NASDAQ:NVCT NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.12+3.4%$1.74$1.09▼$7.22$145.57M2.971.53 million shs750,601 shsHYPDHyperion DeFi$7.08-14.3%$8.15$0.85▼$93.60$46.28M2.42914,650 shs376,612 shsNVCTNuvectis Pharma$6.80-2.3%$8.19$4.44▼$11.80$145.42M-0.26195,546 shs98,413 shsPBYIPuma Biotechnology$3.07-1.3%$3.42$2.22▼$4.13$154.35M1.3308,127 shs230,766 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics+3.41%-6.19%+39.47%+21.84%-68.36%HYPDHyperion DeFi-14.29%-8.05%-55.25%+505.13%-92.92%NVCTNuvectis Pharma-2.30%-12.60%-9.57%-26.49%+7.09%PBYIPuma Biotechnology-1.29%-6.40%-13.76%-4.36%-14.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCCCC4 Therapeutics2.3766 of 5 stars3.34.00.00.01.11.70.6HYPDHyperion DeFi0.3683 of 5 stars1.00.00.00.02.20.80.6NVCTNuvectis Pharma2.5431 of 5 stars3.50.00.00.01.75.00.6PBYIPuma Biotechnology3.633 of 5 stars3.52.00.00.00.04.23.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.50Moderate Buy$12.00466.04% UpsideHYPDHyperion DeFi 2.00Hold$2.00-71.75% DownsideNVCTNuvectis Pharma 3.00Buy$17.00150.00% UpsidePBYIPuma Biotechnology 3.00Buy$7.00128.01% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.58M4.23N/AN/A$3.06 per share0.69HYPDHyperion DeFi$60K660.80N/AN/A($695.52) per share-0.01NVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/APBYIPuma Biotechnology$230.50M0.66$0.84 per share3.65$1.88 per share1.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%8/7/2025 (Estimated)HYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.773.998.08N/A16.37%49.35%18.25%8/7/2025 (Estimated)Latest HYPD, PBYI, NVCT, and CCCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CCCCC4 Therapeutics-$0.41N/AN/AN/A$5.24 millionN/A8/7/2025Q2 2025PBYIPuma Biotechnology$0.11N/AN/AN/A$52.00 millionN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25N/AN/AN/AN/AN/A5/19/2025Q1 2025HYPDHyperion DeFi-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A5.705.70HYPDHyperion DeFiN/A0.340.34NVCTNuvectis PharmaN/A3.283.28PBYIPuma Biotechnology0.111.531.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%HYPDHyperion DeFi25.84%NVCTNuvectis Pharma96.77%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%HYPDHyperion DeFi10.86%NVCTNuvectis Pharma30.52%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.01 million64.81 millionOptionableHYPDHyperion DeFi405.60 million5.00 millionOptionableNVCTNuvectis Pharma820.89 million14.52 millionNot OptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableHYPD, PBYI, NVCT, and CCCC HeadlinesRecent News About These CompaniesPuma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years ago2 hours ago | finance.yahoo.comPuma Biotechnology (PBYI) Projected to Post Earnings on ThursdayJuly 31 at 4:33 AM | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200-Day Moving Average - Here's What HappenedJuly 30 at 4:26 AM | marketbeat.comPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial ResultsJuly 24, 2025 | businesswire.comAlessandra Cesano Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJuly 23, 2025 | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $90,990.00 in StockJuly 23, 2025 | insidertrades.comAdd These 4 Top-Ranked Liquid Stocks to Boost Portfolio ReturnsJuly 15, 2025 | zacks.comPuma Biotechnology (NASDAQ:PBYI) Share Price Passes Above 200-Day Moving Average - Here's WhyJuly 15, 2025 | marketbeat.comAre Investors Undervaluing Puma Biotechnology (PBYI) Right Now?July 14, 2025 | zacks.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for ... - NasdaqJuly 12, 2025 | nasdaq.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $12,188.22 in StockJuly 11, 2025 | insidertrades.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $12,188.22 in StockJuly 10, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells 4,374 Shares of StockJuly 10, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Sells 21,580 Shares of StockJuly 10, 2025 | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 25,592 SharesJuly 10, 2025 | marketbeat.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value InvestorsJuly 10, 2025 | zacks.comPuma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average - Should You Sell?July 5, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | businesswire.comIs Puma Biotechnology (PBYI) Stock Undervalued Right Now?June 27, 2025 | zacks.comFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain - NasdaqJune 26, 2025 | nasdaq.comPuma Biotechnology: Updated Timelines And A Resurgence In SentimentJune 25, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHYPD, PBYI, NVCT, and CCCC Company DescriptionsC4 Therapeutics NASDAQ:CCCC$2.12 +0.07 (+3.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.16 +0.04 (+1.89%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Hyperion DeFi NASDAQ:HYPD$7.08 -1.18 (-14.29%) As of 08/1/2025 04:00 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Nuvectis Pharma NASDAQ:NVCT$6.80 -0.16 (-2.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.80 +0.00 (+0.01%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Puma Biotechnology NASDAQ:PBYI$3.07 -0.04 (-1.29%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.06 0.00 (-0.16%) As of 08/1/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
